• Krystal Biotech recently filed a response with the U.S. Patent and Trademark Office for its KB801 gene therapy, disclosing past data from a discontinued neurotrophic keratitis study in which one patient experienced complete closure of a persistent corneal epithelial defect without reported serious safety issues.
• The company emphasized that this previously undisclosed, single-patient outcome is being shared now only because it will appear in the public patent record and should not be interpreted as evidence of KB801’s overall safety or efficacy.
• We’ll now explore how this isolated but clinically specific KB801 patient outcome could influence Krystal Biotech’s broader investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.

Krystal Biotech Investment Narrative Recap

To be a shareholder in Krystal Biotech, you need to believe that VYJUVEK can sustain profitable growth while the pipeline, including KB801, matures into additional commercial assets. The new KB801 patent disclosure is not a meaningful clinical data update and does not change the near term focus on the pivotal KB801 readout as the key catalyst, nor does it materially alter the main risk, which remains Krystal’s dependence on VYJUVEK-driven cash flows.

Among recent announcements, the UK approval of VYJUVEK in May 2026 stands out most in this context, because it reinforces how much Krystal’s current value is anchored in broadening VYJUVEK access while KB801 and other programs are still in development. As you think about KB801’s isolated single patient outcome, it is worth keeping in mind that near term revenue visibility still hinges far more on execution around new VYJUVEK launches in Europe and Japan.

Yet investors should also be aware that if KB801’s pivotal trial underperforms, Krystal’s reliance on VYJUVEK and its inherent revenue “waviness” could...

Krystal Biotech's narrative projects $1.0 billion revenue and $552.3 million earnings by 2029. This requires 34.8% yearly revenue growth and about a $327 million earnings increase from $225.0 million today.

Uncover how Krystal Biotech's forecasts yield a $361.67 fair value, a 7% upside to its current price.

Exploring Other Perspectives

Some analysts were already expecting revenue to reach about US$1.4 billion and earnings around US$947.2 million by 2029, which is far more optimistic than consensus and could shift meaningfully as new KB801 data and CF or ophthalmology readouts emerge.

Explore 5 other fair value estimates on Krystal Biotech - why the stock might be worth over 3x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Krystal Biotech research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Krystal Biotech research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Krystal Biotech's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Uncover the next big thing with 21 elite penny stocks that balance risk and reward.
• Capitalize on the AI infrastructure supercycle with our selection of the 54 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.